Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy-Reference-Cited by-同舟云学术

Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy

Published:2015-06-03 Issue:8 Volume:35 Page:1923-1933
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Al Marzooqi Saeed H.¹^ORCID,Feld Jordan J.¹

Affiliation:

1. Toronto Centre for Liver Disease; University of Toronto; Toronto ON Canada

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12861/fullpdf

Reference64 articles.

1. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial;Everson;Hepatol Baltim Md,2006

2. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?;Thabut;J Hepatol,2010

3. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis;Bruno;J Hepatol,2013

4. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis;Poordad;N Engl J Med,2014

5. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection;Reiberger;Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc,2011

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis;BMJ Open;2023-06

2. Sofosbuvir-based antiviral therapy provided highly treatment efficacy, safety and good tolerability for Taiwanese chronic hepatitis C patients with decompensated cirrhosis;Journal of the Chinese Medical Association;2021-11-09

3. Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China;Journal of Clinical and Translational Hepatology;2021-05-12

4. Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection;Hepatology Research;2020-10-20

5. Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis;Hepatology Research;2020-09-11